Atopic Dermatitis
Conditions
Interventions
Case series:Two times a day for 20 consecutive days
Sponsors
Peking University People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Male and female patients aged over 18 years; 2. Clinical diagnosis of Atopic Dermatitis (Course of disease >=6 month, BAS 10% to 30%); 3. Have a baseline IGA of >=3; 4. Willing and able to comply with the protocol, provide written informed consent prior to the initiation of any study-related procedures.
Exclusion criteria
Exclusion criteria: 1. Pregnancy, lactation or who plan to be pregnant; 2. Any other skin diseases that may affectt the evaluation of the test results, or the presence of scars, fetal plaques tattoos, etc.in the affected area may affect the evaluation of skin lesions; 3. Skin lesions are confined to the hands and feet; 4. Obvious skin local bacterial,viruses and fungal infections; 5. The following therapists were used within the following time limitsbefore enrollment: (1) Using topic anti-inflammatory drugs within 2 weeks,(including glucocorticoid or calcineurin inhibitors such as atopic dermatitis treatment; (2) Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks before the baseline visit and any phototherapy (including laser), photo-chemotherapy within four weeks prior to the baseline visit; 6. Have obvious heart,lung,gastrointestinal, liver, kidney, blood, nerve and mental illness,and the condition is unstable; 7. Suffering from mental illness, or other causes that may interfere with the trial; 8. A history of malignant tumors; 9. ALT or AST representing liver function is two times larger than the upper limit of normal value, or serum creatinine representing renal function, is higher than the upper limit of normal value; 10. Known or suspected hypersensitivity to any of the constituents of the investigational product; 11. Alcohol,drug addiction and drug dependence; 12. Treatment with other investigational drugs within three months of day 0 or current participation in another clinical trial; 13. The subjects may not participate the study because of other reasons, or whose researchers think are unsuitable for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| EASI; | — |
Countries
China
Contacts
Public ContactJianzhong Zhang
Peking University People's Hospital
Outcome results
None listed